SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eiko Lifesciences informs about newspaper publication

27 May 2026 Evaluate
Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, Eiko Lifesciences has enclosed a copy of newspaper publication in the following newspapers dated 27th May, 2026 with respect to Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Year ended 31st March, 2026 approved at the meeting of Board of Directors held on Tuesday, 26th May, 2026: 1. Mumbai Lakshadeep (Marathi), 2. Financial Express (English). Copy of the results are also uploaded on the website of the Company - www.eikolifesciences.com.

The above information is a part of company’s filings submitted to BSE.

Eiko Lifesciences Share Price

51.51 0.00 (0.00%)
10-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
SRF 2705.15
BASF India 3259.80
Tata Chemicals 717.05
Pidilite Inds. 1499.55
Deepak Nitrite 1640.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×